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Andrew Knight, Animal Consultants International

ABSTRACT
Biomedical research on captive chimpanzees incurs substantial nonhuman animal welfare, ethical, and financial
costs that advocates claim result in substantial advancements in biomedical knowledge. However, demonstrating
minimal contribution toward the advancement of biomedical knowledge generally, subsequent papers did not cite
49.5% (47/95), of 95 experiments randomly selected from a population of 749 published worldwide between 1995
and 2004. Only 14.7% (14/95) were cited by 27 papers that abstracts indicated described well-developed methods for
combating human diseases. However, detailed examination of these medical papers revealed that in vitro studies,
human clinical and epidemiological studies, molecular assays and methods, and genomic studies contributed most to
their development. No chimpanzee study made an essential contribution, or, in most cases, a significant contribution
of any kind, to the development of the medical method described. The approval of these experiments indicates a
failure of the ethics committee system. The demonstrable lack of benefit of most chimpanzee experimentation and its
profound animal welfare and bioethical costs indicate that a ban is warranted in those remaining countries—notably
the United States—that continue to conduct it.

Chimpanzees are the species most closely related to humans and, consequently, the species most likely to be
predictive of human outcomes when used in biomedical research. Hence, some advocate their use as models of
humans in toxicity testing and research procedures that would be unethical to perform on people. The use of
nonhuman primates (NHPs) such as chimpanzees is advocated for studies of hematology, immunology,
pharmacology, virology (Herodin, Thullier, Garin, & Drouet, 2005), neurotoxicology (Evans, 1990), and of potential
bioterrorism agents such as anthrax, Ebola virus, Lassa virus, and the plague (Patterson & Carrion, 2005).
Chimpanzees are postulated to predict human pharmacokinetics—the time course of absorption, distribution,
metabolism, and excretion of pharmaceutical agents—more accurately than other species in the laboratory: rats,
dogs, and even other NHPs, making them the test model of choice for human toxicity testing and drug development
(Wong et al., 2004). In a recent, prominent plea for increased funding for biomedical research on chimpanzees,
VandeBerg et al. (2005) stated that such research has been of critical importance during our struggles against major
human diseases. Similarly, British scientists recently called for the right to conduct such research on chimpanzees—
contrary to the existing UK ban—in rare scenarios, such as the investigation of dangerous, emerging infectious
diseases (Jha, 2006).
However, the similarities between humans and chimpanzees—when combined with the particularly high costs of their
procurement and maintenance—also raise exceptional animal welfare, ethical, and financial concerns when these
highly sentient creatures are experimented on in laboratories (Sauer, 2000; Thew, 2002). Some postulate that the
genetic similarities of chimpanzees to humans—claimed to make them so useful as experimental models—are
precisely what confers upon them a similar ability to suffer (de Waal, 1982, 1996; Goodall, 1986), making it unethical
to confine and experiment upon them (Goodall & Bekoff, 2002; Sauer, 2000; Thew, 2002). In addition, the high cost
of chimpanzee research is increasingly problematic as competition for scarce research funds intensifies.
The first step in assessing the merits or otherwise of biomedical research on captive chimpanzees must be to obtain
a clear picture of the disciplines examined by such research. The United States conducts more research on primates
than any other country in the world—approximately 58,000 versus 11,000 annually—more than 5 times the number
used in the entire European Union (Conlee, 2004). More than 2,200 chimpanzees were believed to be used in
laboratories worldwide in 1993, more than 75% of whom were used in the United States (Stephens, 1995). Although
the numbers had substantially fallen, 1,171 remained available for research in U.S. laboratories by 2005 (VandeBerg
et al., 2005).

To provide a recent assessment, Conlee, Haffeld, and Stephen, (2004) surveyed the Computer Retrieval of
Information on Scientific Projects (CRISP) database, which contains U.S. federally funded, extramural, biomedical
research projects; and PubMed (www.PubMed.com), a biomedical literature portal containing Medline, the U.S.
National Library of Medicine’s premier bibliographic database and related papers and citations. Based on 184 grant
abstracts filed in CRISP and 89 biomedical journal articles cited in PubMed, some initial indications were gained of
the disciplines investigated by U.S. chimpanzee research. A much larger survey, however, is required for
definitiveness. Carlsson, Schapiro, Farah, and Hau (2004) surveyed 2,937 articles published in 2001 describing
4,411 NHP studies that used more than 41,000 primates worldwide; however, only a small minority of these used
chimpanzees.
To gain a clear overview of the biomedical disciplines investigated via research on captive chimpanzees or
chimpanzee tissues, I surveyed three major biomedical bibliographic databases and examined published studies
conducted worldwide from 1995 to 2004. I focused on research on captive chimpanzees, particularly when invasive,
because such research has raised the most concerns
To assess the utility of chimpanzee research in combating human diseases in particular, I determined the frequency
with which these randomly selected chimpanzee studies had been cited by papers describing prophylactic,
diagnostic, or therapeutic methods efficacious in combating human diseases.
METHODS
Three biomedical bibliographic databases were searched for published papers describing research conducted on
captive chimpanzees or chimpanzee tissues from 1995 to 2004 inclusive: CAB Abstracts, the most comprehensive
bibliographic database covering the applied life sciences, containing over 4.5 million records (Anonymous, n.d. a, b);
EMBASE, the Excerpta Medica database, which is a biomedical and pharmacological database containing more than
10 million records (Anonymous, n.d. c); and Medline, the leading medical and allied health profession database,
containing more than 12 million records (Anonymous, 2005). Jointly, these databases included more than 6,000
biomedical journals and thousands of other scientific documents sourced from more than 140 countries.
One of my key objectives was to determine the frequency with which chimpanzee research was cited by papers
describing methods efficacious in combating human diseases; hence my survey was limited to these major
databases likely to contain human medical papers. Primate-specific databases such as Primate Lit were excluded.
All titles, abstracts, and associated fields were searched for the following terms: chimpanzee, bonobo, Pan
troglodytes, and Pan paniscus. In addition, the search was limited to documents with abstracts. Language or other
limitations were not applied. To focus on research on captive chimpanzees, particularly when invasive, the following
papers were included:
•
•
•

studies of captive chimpanzees;
studies of biometric information taken from captive chimpanzees, such as magnetic resonance imaging
scans; and
studies of fresh or preserved chimpanzee tissues, other than those specified.

The following papers were excluded:
•
•
•
•
•
•
•

studies of free-living chimpanzees;
veterinary medical case reports of the diagnosis, treatment, or post-mortem examination of naturally ill
chimpanzees, whether or not in captivity;
genome studies, other than of experimentally infected chimpanzees;
studies of skeletal anatomy (which frequently used museum specimens);
studies of cell lines (although I did include cell samples obtained from captive chimpanzees);
studies of primate blood where the sources or species used were unspecified; and
secondary analyses of data obtained in primary studies.

A total of 749 chimpanzee studies were located that met these inclusion criteria. Resource constraints prevented
detailed examination of all these studies; hence, an appropriate sample size was required from which to estimate the
proportion of chimpanzee studies subsequently cited by other published papers. When calculating the sample size
required, the relatively small population of 749 chimpanzee studies necessitated the use of the more accurate normal
approximation to the hypergeometric distribution, rather than the normal approximation to the binomial distribution
commonly used for large populations (Morris, n.d.; Green, 1982).
The hypergeometric formula used was:

Minimum sample size n =

𝑁𝑧 2 𝑝𝑝

(𝐸2 (𝑁 −1) + 𝑧 2 𝑝𝑝)

(Green, 1982; Guenther, 1973; Morris, n.d.)

where (a) N = population size = 749; (b) z specifies the desired confidence interval (CI), z = 1.96 for a 95% CI; (c) p
and q are population proportions, which were initially unknown, and which were both set to 0.5 to yield the most
conservative possible outcomes; (d) E = the desired accuracy of the sample proportions for the confidence interval
chosen. For an accuracy of +/– 10%, E = 0.1.
Hence, the minimum sample size required to achieve 95% confidence intervals with an accuracy of at least plus or
minus 10%, for the sample proportions derived, was 86. An increased accuracy of plus or minus 5%, for example,
would have been preferable; however, this would have required a sample size of 255, and detailed examination of a
sample of this size was not possible due to resource constraints.
To select at least 86 viable chimpanzee studies for examination from the population of 749, the “Research
Randomizer” random number generator (www. randomizer.org) was used to generate a sample of 100 chimpanzee
studies. For four of these studies, citing papers were not available through the bibliographic databases used, and one
additional study was cited only by a paper for which no abstract was available. Resource constraints precluded initial
screening of papers lacking abstracts; hence, these studies were excluded from further consideration, leaving 95
chimpanzee studies in the sample.
These 95 studies were examined to determine the proportion that were subsequently cited by papers of any kind and
also by medical papers, specifically, that were published and included within these bibliographic databases by
January 2006. Confidence intervals of 95% were then calculated for these proportions via the modified Wald method,
available through the online statistical calculators at http://www.graphpad.com/quickcalcs/index.cfm, described in
Agresti and Coull (1998) as providing more accurate results than the so-called exact method commonly used. The
species and biomedical disciplines that were the focus of these citing papers were also ascertained.
Where abstracts of citing papers indicated the existence of prophylactic, diagnostic, or therapeutic methods with clear
potential for combating human diseases, the complete medical papers were obtained and reviewed in detail to
determine the contribution of the cited chimpanzee study to the development of the medical method described, in
comparison with other cited sources of knowledge.
RESULTS
Bibliographic databases are constantly updated. As of August 28, 2005, 2,400 abstracts were located using the
specified search terms. Of these, 749 were found to be studies of captive chimpanzees or chimpanzee tissues that
met the inclusion criteria, of which 48.5% (363/749) were biological experiments; 41.5% (311/749) were virological
experiments (Figure 1).
Biological investigations were conducted in nine disciplines, of which the most frequent (Figure 2) were
cognition/neuroanatomy/neurology (36.6%, 133/363) and behavior/communication (20.7%, 75/363).

FIGURE 1 Chimpanzee experiments 1995–2004 (total 749).

FIGURE 2 Biology experiments (363 of 749).

Virological investigations were conducted in 30 disciplines, of which the most frequent were hepatitis C virus (HCV)
and human immunodeficiency virus (HIV), which both comprised 31.2% (97/311) of all virology experiments (Figure
3).
Therapeutic investigations comprised 3.5% (26/749) of all chimpanzee experiments, of which 61.5% (16/26)
investigated the pharmacological properties of various compounds. Other experiments included the testing of surgical
techniques or prostheses, anesthesiological and toxicological investigations (Figure 4).

FIGURE 3 Virology experiments (311 of 749).

FIGURE 4 Therapeutic investigations (26 of 749).

Parasitology experiments comprised 3.1% (23/749) of all chimpanzee experiments. Eight parasitic species were
investigated, of which the most frequent (Figure 5) were the malaria protozoa Plasmodium falciparum and P. ovale
(26.1%, 6/23), the roundworm Onchocerca volvulus (21.7%, 5/23), and the flatworm Schistosoma mansoni (17.4%,
4/23).
Other diseases and miscellaneous experiments together comprised 3.5% (26/749) of all chimpanzee experiments.
The most frequent (Figure 6) were investigations of laboratory/husbandry techniques (42.3%, 11/26) and
endotoxemia (30.8%, 8/26). Radiation studies were also conducted, and four other diseases were investigated,

namely, benign prostatic hyperplasia, Creutzfeldt-Jakob disease, gastrointestinal bacteriology (Bacillus thuringiensis),
and tuberculosis (Mycobacterium tuberculosis).
FIGURE 5 Parasitology experiments (23 of 749).

FIGURE 6 Other diseases and miscellaneous experiments (26 of 749).

Citations of Chimpanzee Studies
Ninety-five chimpanzee studies were randomly selected from the population of 749 published between 1995 and
2004. Of these, 49.5% (47/95; 95% CI = 39.6–59.4%) were not cited by any subsequent papers (Figure 7).

FIGURE 7 Citations of 95 randomly selected published chimpanzee studies.

FIGURE 8 Chronological distribution of 48 cited chimpanzee studies.

A total of 48 cited chimpanzee experiments were distributed fairly evenly across the decade (Figure 8).
These 48 chimpanzee studies were cited by 143 papers with abstracts and by 17 additional papers that lacked
abstracts. Examination of these abstracts indicated that 35.8% (34/95; 95% CI = 26.9–45.8%) of all chimpanzee
studies were cited by 116 papers that clearly did not describe well-developed prophylactic, diagnostic, or therapeutic
methods for combating human diseases. Some of these citing papers focused on humans in isolation or in
combination with a variety of other species ranging from bacteria to elephants, including a large variety of primate
species.
Various biological disciplines were investigated in these citing papers. Hepatitis viruses, cognition, and HIV—in that
order—featured most prominently, although a substantial number of others were included (see Appendix).
Citing studies in this set that focused on humans as a primary subject examined a variety of disciplines other than
pathology, or etiological or other aspects of human diseases. In a few cases, potential prophylactic, diagnostic, or

therapeutic methods for combating human diseases were mentioned, however, all fell well short of being sufficiently
developed for human use.
Citing Medical Papers
A total of 27 papers cited 14.7% (14/95; 95% CI = 8.9–23.4%) of all chimpanzee studies. These studies described
diagnostic methods (5) or prophylactic and/or therapeutic methods (22) for combating human diseases that abstracts
indicated were fully developed—or in the latter stages of being developed—for human use. Diseases examined
included cancer (non-specific), chronic obstructive pulmonary disease (COPD), Epstein-Barr virus (EBV), hepatitis
viruses A through G (HAV through HGV), hepatocellular carcinoma (HCC), HIV, malaria, organ transplant rejection,
respiratory syncytial virus (RSV), rheumatoid arthritis (RA), rhinovirus colds, systemic lupus erythematosus (SLE),
and transmissible spongiform encephalopathies (TSEs) (Table 1).
DISCUSSION
Utility of Chimpanzee Studies in Advancing Biomedical Knowledge
On the face of it, studies of captive chimpanzees or chimpanzee tissues appear to have contributed to a large array
of biomedical disciplines. However, not all knowledge has significant value or is worth the ethical and financial costs
that may be incurred in gaining that knowledge. A universally accepted principle of sound experimental science
involving human or nonhuman animal subjects is that the welfare-related, bioethical, financial, and other costs of a
proposed experiment must be exceeded by the benefits reasonably expected to result. This is particularly important
when potentially harmful research on non-consenting subjects is being contemplated, as is the case with much
research on captive chimpanzees. In most research centers worldwide, institutional ethics committees are required
by legislation to make such assessments and are expected to veto proposed experiments in which the benefits are
not likely to exceed the costs.
Given that almost all of these 749 chimpanzee studies recently conducted worldwide would have been approved by
ethics committees entrusted with engaging in precisely such deliberation, it is reasonable to expect that these
experiments would have yielded significant benefits. However, this examination of 95 randomly selected chimpanzee
studies revealed that half were not cited by any papers subsequently published and included in the comprehensive
bibliographic databases examined. The year of publication did not appear to substantially affect this outcome, as
citation frequencies were similar across the decade, with more recent papers cited approximately as often as older
papers.
Citation frequencies are not, of course, a definitive indication of the benefits or lack thereof of scientific research.
Uncited studies may also contribute to the advancement of biomedical knowledge through unpublished
communications of results between scientists, the use of published studies without citation, and— potentially in the
future—where recognition of the importance of results is delayed.
A potentially more accurate means of assessing the value of studies might be through detailed, individual
examination of their aims, methods, results, and conclusions. However, resource constraints usually prevent such
detailed examination of large numbers of studies. However, examination of smaller numbers may be feasible, once
studies of interest are identified through initial screening measures, including citation analyses. In fact, precisely such
a process occurred during this review. Such detailed individual assessments are, however, also more likely to vary
between individuals.
Citation rates are not entirely objective either and may be affected by whether the study outcomes support the
hypotheses under consideration, and by article length, number of authors, their country and university of affiliation
(Leimu & Koricheva, 2005).
The degree to which a journal is circulated and read within the scientific community may also affect the likelihood that
papers published within it will be cited. Journal impact factors (JIFs) attempt to quantify such probabilities based
largely on annual assessments of journal citation frequencies. Hence, it is possible that the disappointing citation rate
of this sample of chimpanzee studies was due to their publication in lower impact-factor journals, when compared
with publication norms. However, the randomness of the selection of this reasonably sized sample makes it likely that

the impact factors of these journals were broadly similar to those of the larger population of journals in which the
entire population of chimpanzee studies were published. It may be true that chimpanzee studies are generally
published in journals with lower JIFs; however, this would also be a reflection of the lack of importance accorded to
these studies and a potential cause of their lowered citation rates.

TABLE 1 Twenty-Seven Medical Papers Citing Chimpanzee Studies

Paper

Human Disease
Investigated

Medical Approach:
Prohylactic,
Diagnostic,
Therapeutic

Citing Medical Paper

Paper Type

Review
Refs

Cited Chimpanzee
Study

1

Cancer (non-specific)

Ther

Tong & Stone (2003)

Review

155

Brams et al. (2001)

2

COPD

Prophy

Suzuki et al. (2001)

Research

3

EBV

Prophy

Khanna et al. (1999)

Review

112

Bertoni et al. (1998)

4

HAV & HBV

Prophy

Koff (2002)

Review

85

Ogata et al. (1999)

5

HAV–HGV

Prophy, Ther

Regev & Schiff (1999)

Review

71

Mast et al. (1998)

6

HBV

Prophy

McMahon et al. (2005)

Research

7

HBV

Prophy, Ther

Karayiannis (2003)

Review

8

HCV

Diag

Hüssy et al. (1997)

Research

9

HCV

Ther

Feld & Hoofnagle (2005)

Review

10

HCV

Ther

Nakano et al. (1999)

Research
Review

Huguenel et al. (1997)

Ogata et al. (1999)
300

Pancholi et al. (2001)
Wang et al. (1996)

91

Bigger et al. (2001)
Wang et al. (1996)

11

HEV

Prophy

Worm & Wirnsberger
(2004)

12

HEV

Diag

Obriadina et al. (2002)

Research

13

HCC

Diag

Kim & Wang (2003)

Review

14

HIV

Prophy, Ther

Armbruster et al. (2002)

Research

Conley et al. (1996)

15

HIV

Prophy, Ther

Armbruster et al. (2004)

Research

Conley et al. (1996)

Bardsley-Elliot & Perry
(2000)

Review

130

Grob et al. (1997)

133

Mast et al. (1998)
Mast et al. (1998)

81

Bigger et al. (2001)

16

HIV

Prophy, Ther

17

HIV

Prophy

Hone et al. (2002)

Review

108

Conley et al. (1996)

Review

93

Conley et al. (1996)

Research

18

HIV

Prophy, Ther

Sleasman & Goodenow
(2003)

19

HIV

Diag

Yang et al. (1998)

20

HIV

Ther

Gallo (2002)

Review

258

Goh et al. (1998)

21

Malaria

Prophy

Moore & Hill (2004)

Review

104

Pancholi et al. (2001)

22

Organ transplant rejection

Ther

Matthews et al. (2003)

Review

87

Newman et al. (2001)

23

RSV

Prophy

Kneyber & Kimpen (2002)

Review

150

24

RA

Ther

Hepburn et al. (2003)

Research

Newman et al. (2001)

25

Rhinoviral colds

Prophy

Turner et al. (1999)

Research

Huguenel et al. (1997)

26

SLE

Ther

Gescuk & Davis (2002)

Review

27

TSE

Diag

Brown (2005)

Review

Conley et al. (1996)

Crowe et al. (1999)

77

Brams et al. (2001)

26

Cervenakova et al.
(2003)

Note. COPD = chronic obstructive pulmonary disease, EBV = Epstein-Barr virus, HAV–HGV = hepatitis viruses A
through G, HCC = hepatocellular carcinoma, HIV = human immunodeficiency virus, RSV = respiratory syncytial virus,
RA = rheumatoid arthritis, SLE = systemic lupus erythematosus, TSE = transmissible spongiform encephalopathy.

On the other hand, Seglen (1989) found that citation frequencies of articles published by individual authors or
research groups correlated extremely poorly with their corresponding JIFs. Seglen consequently concluded that JIFs
are unsuitable as an indicator of scientific quality. Hence, it appears likely that the disappointing citation rates of
chimpanzee experiments are indeed a reflection of their lack of scientific value rather than the result of a very large
number of consistently unfortunate journal choices.
Despite their limitations, citation frequencies generally provide a quantifiable and reasonably objective approximation
of utility or lack thereof. Research that makes a significant contribution to a field—such as by confirming or refuting
hypotheses—is very likely to be cited by future papers, as is research that produces interesting or controversial
outcomes. On the other hand, research that is inconclusive or of little interest or significance is much less likely to be
cited.
The disappointing citation rate of these chimpanzee studies is therefore cause for considerable concern. Although
uncited studies may contribute to the advancement of biomedical knowledge through various means, it is
unreasonable to conclude that a large number of studies made a significant contribution—if none were cited by any
future publication, as occurred for half of these randomly selected chimpanzee studies.
Given that research of lesser significance is not published at all, these published chimpanzee experiments can be
assumed to be those with the greatest potential for advancing biomedical knowledge. Consequently, these results
indicate that the majority of captive chimpanzee research generates data of questionable value, which makes little
obvious contribution toward the advancement of biomedical knowledge.
Ethics committees are generally required by legislation, and expected by society, to allow only those experiments in
which the benefits are likely to exceed the costs. The welfare-related, bioethical and financial costs integral to
chimpanzee experimentation are profound (Anonymous, 1995; Balls, 1995; Langley, 2006; Scharmann, 2000; Smith
& Boyd, 2002). The benefits accruing from these chimpanzee experiments, on the other hand, were clearly
questionable. Because very few research fields incur similar costs, even favorable citation rates—compared to other
fields of research—would not alter this assessment. Therefore, the approval of large numbers of these experiments,
despite their questionable value, indicates a widespread failure of the ethics committee system.
Utility of Chimpanzee Studies in Combating Human Diseases
Most would consider that the greatest justifications for research on captive chimpanzees involve attempts to advance
human health. Advocates of such research claim its critical importance during our struggles against major human
diseases (VandeBerg et al., 2005). However, only 14.7% of these randomly selected chimpanzee studies were cited
by a total of 27 papers that abstracts indicated might describe well-developed methods for combating human
diseases.
As stated, citation rates are not a definitive indication of utility or lack thereof. Chimpanzee studies may have
contributed to medical advances through various indirect means, such as by stimulating investigation of certain lines
of inquiry in humans, although it is unlikely that any medical papers subsequently published would not cite the
chimpanzee studies that provided such inspiration. Alternatively, chimpanzee studies may have contributed to
investigations of disease etiology or to papers describing prophylactic, diagnostic, or therapeutic methods for
combating human diseases in early stages of development—although potential human benefits, in such cases,
remain speculative.
However, it is reasonable to expect that if chimpanzee research had truly been of critical importance during struggles
against major human diseases, as claimed by advocates, such chimpanzee studies would be cited by papers
describing methods efficacious in combating those diseases. The only remaining possibility is that none of the
struggles—to which chimpanzee research purportedly made major contributions—resulted in effective, published
solutions.
In fact, some papers describing well-developed prophylactic, diagnostic, or therapeutic methods for combating human
diseases cited chimpanzee studies. The contribution of the cited chimpanzee study to these papers, in comparison to
other cited sources of knowledge, deserves closer scrutiny.

Sources Contributing to Medical Papers
Twenty-seven medical papers cited randomly selected chimpanzee studies. Methods that featured frequently in the
development of the medical methods described included (a) in vitro studies, (b) human clinical and epidemiological
studies, (c) molecular assays and methods, and (d) genomic studies. Four methods, featuring particularly prominently
in various cases, were used in at least 18 papers:
1.
2.
3.

4.

In vitro studies, such as of human T-cells, HeLa cells, human respiratory epithelium (embryonic lung
fibroblasts), human adenoid explants, lymphoblastoid and rodent cells lines, were used in at least 18 papers;
Human clinical and epidemiological studies were used in at least 15 and 6 medical papers, respectively;
Molecular methods, such as immune electron microscopy, radioimmunoassay, polymerase chain reaction
(PCR), enzyme-linked immunosorbent assay (ELISA), Western blot, and several assays designed for the
diagnosis of TSEs: a combination of competitive antibody capture and capillary electrophoresis,
conformation-dependent immunoassay, screening for intensely fluorescent targets, and an immuno-PCR
assay, were used in at least 8 medical papers; and
Genomic techniques—such as serial analysis of gene expression and microarray analysis of viral genomes,
for example; suppression subtractive hybridization; representational difference analysis; and differential
display—featured more prominently in 4 medical papers.

Several viral studies used E. coli and baculoviruses in conjunction with Sf9 insect cells as vectors for viral delivery
and expression.
Chimpanzee studies were, of course, cited by all the medical papers. Additional animal models were cited more
prominently in five medical papers. Models included genetically modified and unmodified mice, rats, hamsters, guinea
pigs, sheep, goats, cows, mink, woodchucks, and NHPs (baboons, orangutans, cynomolgus monkeys, and rhesus
macaques). Several of these species were cited in only one paper (Brown, 2005) that described diagnostic methods
for combating TSEs, either as sources or recipients of TSE-infected tissues.
A detailed examination of the contributions—or otherwise—of animal models other than chimpanzees was beyond
the scope of this study. However, as Brown (2005) aptly put it, “… it is always problematic to what extent such
models reflect the human situation” (pp. 66, 67).
Contributions Made by Chimpanzee Studies
The randomly selected chimpanzee studies proved to be of peripheral importance to most of these medical papers
for a variety of reasons. Of these papers, 63.0% (17/27) were wide-ranging reviews of 26–300 (median 104)
references, to which the cited chimpanzee study made a very small contribution. In 12 cases (Table 1: papers 5, 8–
13, 16, 20, 24–25, 27), the chimpanzee studies appeared redundant because humans or human sera were studied
concurrently or because they served only to confirm previous human observations. In 7 cases (Table 1: papers 2, 22–
27), the method explored in the cited chimpanzee study was not developed further, sometimes because later clinical
trials in humans failed to demonstrate safety or efficacy, contrary to positive chimpanzee results. In 5 cases (Table 1:
papers 3–4, 13, 21, 25), the chimpanzee study examined a disease or method of only peripheral relevance to the
medical method described. In 3 cases (Table 1: papers 2, 17, 19), the chimpanzee study merely illustrated a
historical finding or was cited only during historical discussions of attempts to combat the disease in question. In
another 3 cases (Table 1: papers 7, 17, 26), the chimpanzee studies yielded results inconsistent with data from other
NHP studies; in 2 cases (Table 1: papers 18, 24), they yielded results inconsistent with human data. In 2 more cases
(Table 1: papers 8, 10), only the human outcomes from concurrent human studies—described within the cited
chimpanzee studies—were discussed. In 1 case (Table 1: paper 12), the chimpanzee study may have helped
establish the need for a new diagnostic method but did not contribute further to its development.
Five chimpanzee studies were cited by more than one medical paper and deserve closer examination. Bigger, Brasky
& Lanford’s (2001) paper on the effects of HCV in chimpanzees served only to confirm what had already been
observed in earlier human studies cited by Feld & Hoofnagle’s (2005) paper on therapeutic methods for combating
HCV (Table 1: paper 9), and was of peripheral relevance to Kim & Wang’s (2003) paper describing a diagnostic
method for the detection of HCC (Table 1: paper 13).

Conley et al.’s (1996) study of the prophylactic use of human monoclonal antibodies (hMAbs) in chimpanzees
challenged with HIV-1 was cited by five medical papers. In two studies of prophylactic and therapeutic methods for
combating HIV (Armbruster et al., 2002, 2004), positive prior results in the cited chimpanzee study appeared to
suggest a potential field of further development with respect to hMAb choices used in combination prophylactic and
therapeutic regimes (Table 1: papers 14–15). The cited chimpanzee study did not, however, play an integral role in
the citing studies, the purpose of which was to examine the safety, immunogenicity, and pharmacokinetics of hMAb
protocols in clinically healthy HIV-1-infected human volunteers. In papers by Hone et al. (2002) and Yang, D’Souza,
and Vyas (1998), describing the development of a diagnostic method and vaccines, respectively, for combating HIV,
the cited chimpanzee study served only to demonstrate that effective HIV antibodies can indeed neutralize HIV in
chimpanzees to varying degrees, although conflicting results were observed in 6 other NHP studies cited by Hone et
al. (Table 1: papers 17 & 19). The cited chimpanzee study did not otherwise contribute to the development of these
diagnostic and prophylactic methods. The contribution of this study to the development of prophylactic and
therapeutic methods for combating HIV, reviewed by Sleasman and Goodenow (2003), was similarly limited by
inconsistency with other cited human data (Table 1: paper 18).
Mast, Alter, Holland, and Purcell’s (1998) paper describing the poor sensitivity, concordance, and variable efficiency
of previously available HEV assays in chimpanzees, particularly against different HEV strains, was cited by Obriadina
et al.’s (2002) paper describing the development of a diagnostic technique for the detection of HEV (Table 1: paper
12), and by Regev and Schiff’s (1999) review of prophylactic and therapeutic options for combating HAV, HBV, HCV,
HEV, HGV and transfusion-transmitted virus (Table 1: paper 5). The chimpanzees in this study were used as both
positive and negative controls. However, their use was redundant, for more relevant positive and negative human
controls in the form of human sera were concurrently available. In addition, one of Mast et al.’s key outcomes was the
highly discrepant, existing HEV assay results from U.S. blood donors that were presumed HEV negative,
necessitating great caution when interpreting positive assay results. This outcome relied exclusively on human
results.
Newman et al.’s (2001) paper demonstrating the safety and efficacy of Keliximab—a primatized IgG1 anti-CD4
mAb—in modulating T-cell receptor responsiveness in chimpanzees, was cited by two medical papers. In Matthews,
Ramos, and Bluestone’s (2003) review of therapeutic strategies designed to combat organ transplant rejection, it was
hoped that the targeting of cellular receptors might result in T-cell inactivation, thereby delaying allograft rejection; Tcell activation is central to the inflammation and tissue damage that results in such rejection (Table 1: paper 22).
Hepburn, Totoritis, and Davis (2003) also described their clinical trial of Clenoliximab, an anti-CD4 mAb proposed for
the treatment of RA (Table 1: paper 24). However, a later Phase II human clinical trial of an analogue drug
(Zanolimumab) failed to demonstrate efficacy at combating RA, resulting in discontinuation of the development of this
drug for RA patients—also casting doubts upon the efficacy of anti-CD4 mAbs in combating allograft rejection.
A paper describing chimpanzee studies of DNA-based vaccines (Pancholi et al., 2001) was cited both by
Karayiannis’s (2003) review of the prophylactic and therapeutic options available for combating HBV (Table 1: paper
7), and by Moore and Hill’s (2004) review of strategies for the development of a malaria vaccine (Table 1: paper 21).
In the former case, inconsistency with other chimpanzee and NHP results limited the utility of the cited chimpanzee
study; in the latter case, the disease and vaccination strategies explored were too distant from those investigated in
the cited chimpanzee study to accord it more than tenuous relevance.
Wang, Brotman, Andrus & Prince’s (1996) study of the reactivity of humans and chimpanzees to various epitopes of
HCV H-strain structural proteins was cited by both Hüssy et al.’s (1997) paper investigating a diagnostic method for
HCV (Table 1: paper 8), and by Nakano et al.’s (1999) paper investigating therapeutic options for HCV (Table 1:
paper 10). In both cases, however, only the human outcomes concurrently described within this chimpanzee study
contributed to the citing medical paper. In fact, the cited chimpanzee study served mainly to illustrate the differences
in the immune responses of humans and chimpanzees to HCV.
Several authors of human medical papers or cited chimpanzee studies identified potential problems regarding
attempts to extrapolate chimpanzee results to human outcomes. Wang et al. (1996) identified key differences
between the immune responses of humans and chimpanzees to HCV infection. In their study of prophylactic methods
for combating EBV, Khanna, Moss, and Burrows (1999) stated, “It would be a mistake to assume that experimental
results obtained in these … primate models had direct relevance to vaccine formulations that might offer protection

against infectious mononucleosis [one of the main targets for a vaccine]” (p. 54).When commenting on the failure of a
test drug to demonstrate efficacy at combating (T-cell dependent) RA in a phase II clinical trial—despite prior efficacy
of an analogue drug in modulating T-cell receptor responsiveness in chimpanzees, and other clinical failures contrary
to animal in the laboratory successes—Matthews et al. (2003) stated, “… results to date illustrate the profound
difficulties in translating animal model success to the clinical arena” (p. 798). Development of this test drug for RA
patients was discontinued. In his review of prophylactic methods for combating HAV and HBV, Koff (2002) described
the cited chimpanzee study as potentially complicating our understanding of escape viruses.
Factors Limiting the Medical Utility of Chimpanzee Studies
Although just under 15% of these chimpanzee studies were cited by 27 papers that abstracts indicated might
describe well-developed methods for combating human diseases, detailed individual examination of these papers
revealed that in vitro studies; human, clinical, and epidemiological studies; molecular assays and methods; and
genomic studies contributed most to the development of the medical methods described. Studies in a variety of
animal species other than chimpanzees were cited by at least 5 papers, but some authors questioned their
applicability to human outcomes. The chimpanzee studies cited by these 27 medical papers did not appear to
contribute substantially to the development of the medical methods under consideration.
These results suggest a lack of utility of chimpanzees as an experimental model for combating human diseases. On
the face of it, this appears contrary to expectations, given the genetic similarities of chimpanzees to humans. Our two
species shared a common ancestor just 5-7 million years ago—a very short time span in phylogenetic terms. A 2005
draft of the chimpanzee genome confirmed it to be 98.77% identical to the human genome in terms of base pairs
(The Chimpanzee Sequencing and Analysis Consortium, 2005); insertions, deletions, and consequent misalignments,
however, raise the total estimated difference to around 4–5% (Britten, 2002; Varki & Altheide, 2005).
Although a minority of these genetic differences between humans and chimpanzees lie within structural genes, most
are now known to lie within the regulatory regions of our DNA. In regulating the activities of structural genes,
regulatory genes can exert an “avalanche” effect upon hundreds of other genes. Consequently, a small difference
may have profound effects (Bailey, 2005). Striking differences have been found in the levels of gene expression
between chimpanzees and humans in the brain and liver (Ruvolo, 2004).
Although chimpanzees and humans differ in only 4–5% of their DNA, that difference is sufficiently important to result
in a difference of about 20% in protein expression (Glazko, Veeramachaneni, Nei, & Makalowski, 2005), resulting in
marked phenotypic differences between the species: (a) differences in the susceptibility to, etiology and progression
of various diseases; (b) differences in absorption, tissue distribution, metabolism, and excretion of chemotherapeutic
agents; and (c) differences in the toxicity and efficacy of pharmaceuticals (Bailey 2005).
Furthermore, the tissue responses to disease agents and test chemotherapeutics in chimpanzees in the laboratory
are likely to be distorted by the neurological, endocrinological, and immunological abnormalities that result from the
variety of stresses these chimpanzees commonly endure. These include standardized small, barren, laboratory
housing; immobilization; isolation; or—less frequently—overcrowding; aggression from fearful or frustrated cage
mates; trauma; chronic boredom; and a variety of stressful laboratory procedures (Fouts, 1995).
The substantial differences in protein expression between chimpanzees and humans and the further distortions of
normal physiology that result from the stressful laboratory environment and procedures common to chimpanzee
experimentation are the most likely causes of the observed lack of utility of chimpanzee research in the development
of prophylactic, diagnostic, and therapeutic methods efficacious in combating human diseases.
Study Limitations
As stated, one of my key objectives was to determine the frequency with which chimpanzee research was cited by
papers describing methods efficacious in combating human diseases; hence, my survey was limited to major
biomedical bibliographic databases likely to contain human medical papers. Primate-specific databases such as
Primate Lit were excluded. It is possible that greater non-medical utility of these randomly selected chimpanzee
studies might have been evident via such additional database searches. However, the databases searched included
the most comprehensive databases covering the applied life sciences. They contained in excess of 12 million

records, 6,000 biomedical journals, and thousands of other scientific documents sourced from over 140 countries.
Hence, any discrepancies are unlikely to be large, and no contributions of major importance are likely to have been
excluded by my review.
Initial indications of the medical utility of these chimpanzee studies were assessed by examining the 160 papers that
cited 50.5% (48/95) of these studies. Of these 160 citing papers, 143 had abstracts, and 17 (10.6%) lacked them.
Due to resource constraints, these 17 papers were not examined. Hence, it is possible that the true number of
chimpanzee studies cited by medical papers may have been slightly higher than indicated by my results. However,
any such discrepancy is likely to be small; 18.9% (27/143) of the citing papers, for which abstracts were available,
proved to be medical papers of interest. If 18.9% of the 17 unexamined papers had been of similar interest,
approximately only 3 additional medical papers would have resulted, citing—at most—a very few additional
chimpanzee studies.
Approximately 15% of these chimpanzee studies were cited by papers that abstracts indicated might describe welldeveloped methods for combating human diseases. However, detailed examination of the complete medical papers
revealed that their contributions—compared to other cited sources of knowledge—were small. Although these results
clearly demonstrate that chimpanzee studies do not generally make important contributions to the development of
methods efficacious in combating human diseases, they cannot provide conclusions on exceptional cases. Assessing
contributions of any exceptionally valuable chimpanzee studies would require their identification based on citation
frequencies, publication in leading journals, and other indicators of possible value—not on random selection.
Precisely such a strategy was recently employed by Hackam & Redelmeier (2006), who sought to assess the clinical
utility of very highly cited animal experiments—without species limitation—published in the seven leading scientific
journals. Ranked by citation impact factor, these journals regularly publish original animal studies. Of 76 animal
studies located with a median citation count of 889 (range: 639–2,233), only 36.8% (28/76) were replicated in human,
randomized trials; 18.4% (14/76) were contradicted by randomized trials; and 44.7% (34/76) had not been tested.
Ultimately, only 10.5% (8/76) of these medical interventions were subsequently approved for use in human patients.
No similar study focusing specifically on captive chimpanzee research has yet been published.
CONCLUSIONS
The advanced sensory, cognitive, communicative, and social abilities of chimpanzees (Byrne, 1998; de Waal, 1982,
1996; Goodall, 1986, 1995; Hare, Call, Agnetta, & Tomasello, 2000; Tomasello, Call, & Hare, 2003; Whiten & Byrne,
1988) also confer upon them a profound ability to suffer when born into unnatural captive environments or captured
from the wild—as many older research chimpanzees once were—and when subsequently subjected to confinement,
social disruption, and involuntary participation in potentially harmful biomedical research.
Justifications, proposed by advocates for such research, rely upon the critical contributions advocates claim the
research has made to the advancement of biomedical knowledge—in particular, toward combating major human
diseases. However, this systematic review of 95 randomly selected studies of captive chimpanzees, conducted
during a recent decade, revealed that half were not cited by any papers subsequently published and included within
the comprehensive bibliographic databases examined. The review indicated that the studies generated data of
questionable value that made little obvious contribution to the advancement of biomedical knowledge. Given that
research of lesser significance is not published, these results indicate that the majority of chimpanzee experiments
generate data of questionable value.
In addition, closer examination failed to identify any chimpanzee studies that made an essential contribution or—in a
clear majority of cases—a significant contribution of any kind to papers describing well-developed prophylactic,
diagnostic, or therapeutic methods for combating human diseases.
Despite the low utility of chimpanzee experiments in advancing human healthcare indicated by these results, it
remains true that chimpanzees are the species most closely related to human beings. Hence, it is highly likely that
other species are even less efficacious when used as experimental models of humans in biomedical research and
toxicity testing. Given the many millions of other species used annually for these purposes (particularly in the case of
rodents); the profound ethical and financial costs incurred as a result; and the adverse consequences for human

health—if other, potentially more efficacious research models are consequently deprived of funding—systematic
reviews of the utility of other laboratory species in advancing human healthcare are also urgently warranted. These
reviews ought to be conducted by government agencies with oversight for animal research and by others with similar
responsibilities within the commercial and academic sectors.
Furthermore, almost all these chimpanzee experiments—given the profound animal welfare, ethical, and financial
costs integral to chimpanzee experimentation—would have been approved by an institutional ethics committee,
required by legislation to approve only those experiments likely to result in substantial benefits. Although the concept
of ethical review is sound, these results demonstrate that its implementation is presently flawed. This flaw has
resulted from over-reliance on the assumption, in the absence of supportive evidence, that animal experiments are
likely to be of substantial use in advancing biomedical progress.
This systematic study and others, some of which have examined hundreds of randomly selected animal experiments,
have demonstrated that animals—to justify their widespread use as experimental models of humans—are not
sufficiently predictive of the progression of human diseases, human toxicity, or responses to chemotherapeutic
agents (Bailey, Knight, & Balcombe, 2005; Curry, 2003; Hackam & Redelmeier, 2006; Horn, de Haan, Vermeulen,
Luiten, & Limburg, 2001; Jonas, Aiyagari, Vieira, & Figueroa, 2001; Knight, Bailey, & Balcombe, 2006a, 2006b;
Lazzarini, Overgaard, Conti, & Shirtliff, 2006; Lindl, Völkel, & Kolar, 2005, 2006; O’Collins et al., 2006; Perel et al.,
2007; Pound, Ebrahim, Sandercock, Bracken, & Roberts, 2004).
Twenty published systematic reviews examining the human clinical utility of animal experiments were identified during
a recent, comprehensive literature search (Knight, 2007). Authors concluded that animal models were significantly
useful in contributing to the development of clinical interventions or substantially consistent with clinical outcomes in
only two cases—one of which was contentious. Included were reviews of the clinical utility of animal experiments
expected by ethics committees to lead to medical advances and of highly-cited experiments published in major
journals. Seven additional reviews failed to clearly demonstrate utility in predicting human toxicological outcomes
such as carcinogenicity and teratogenicity.
Clearly, the assumption that animal experiments are likely to be of substantial use in advancing biomedical progress
is not supported by most existing evidence. This systematic review has demonstrated that this assumption is no more
correct when applied to chimpanzee experiments. On the other hand, the animal welfare, ethical, and financial costs
of chimpanzee experimentation are particularly high. By approving these experiments on the basis of unfounded
assumptions about their likely benefits, the ethics committees responsible failed in their duty to society and to the
animals they were charged with protecting.
Unless and until credible evidence emerges demonstrating that biomedical research on captive chimpanzees is truly
likely to provide benefits in excess of its profound costs, it seems eminently reasonable to join numerous experts
(Anonymous, 1995; Balls, 1995; Langley, 2006; Scharmann, 2000; Smith & Boyd, 2002) in calling for the banning of
such research in those remaining countries—notably the United States—that continue to conduct it.
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APPENDIX
Biological Disciplines Investigated
Citing papers investigated various biological disciplines in addition to the most prominently featured hepatitis viruses,
cognition, and HIV. These disciplines included the following: asthma, autism, behavior, benign prostatic hyperplasia,
cancer, chronic obstructive pulmonary disease, coxsackievirus B3, Epstein-Barr virus, genetic studies, human
parainfluenza virus type 3, immunology, and Kawasaki disease. In addition, the papers investigated laboratory
techniques including gene expression profiling and cDNA microarray interpretation, leukemia, malaria,
neuroanatomy, neurology, organ transplantation, pathology (clinical), psychology, respiratory syncytial virus,
rheumatoid arthritis, rhinovirus colds, simian immunodeficiency virus, systemic lupus erythematosus, surgical
techniques: cardiac allografts, toxicity: arsenic, transmissible spongiform encephalopathies, and virology: nonspecific.
cDNA microarrays, containing hundreds or thousands of microscopic spots of complementary DNA (cDNA)
transcripts of mRNA templates (from which the non-coding intron sequences of the original DNA have been excised),
offer the ability to examine the expression of large numbers of genes simultaneously. One possible application is the
potential detection of changes in gene expression caused by toxins (toxicogenomics), well prior to more invasive end
points. Allografts are tissues or organs grafted to genetically dissimilar members of the same species.

